Investigational Drug Information for APG-115
✉ Email this page to a colleague
What is the drug development status for APG-115?
APG-115 is an investigational drug.
There have been 8 clinical trials for APG-115.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 12th 2021.
The most common disease conditions in clinical trials are Leukemia, Preleukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd., and Merck Sharp & Dohme Corp.
There is one US patent protecting this investigational drug and sixteen international patents.
Summary for APG-115
| US Patents | 1 |
| International Patents | 16 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2021-07-12) |
| Vendors | 25 |
Recent Clinical Trials for APG-115
| Title | Sponsor | Phase |
|---|---|---|
| APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | Suzhou Yasheng Pharmaceutical Co., Ltd. | Phase 1 |
| APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors | Ascentage Pharma Group Inc. | Phase 1 |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL | Ascentage Pharma Group Inc. | Phase 2 |
Clinical Trial Summary for APG-115
Top disease conditions for APG-115
Top clinical trial sponsors for APG-115
US Patents for APG-115
International Patents for APG-115
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| APG-115 | Australia | AU2015247646 | 2034-04-17 | ⤷ Sign Up |
| APG-115 | Canada | CA2945527 | 2034-04-17 | ⤷ Sign Up |
| APG-115 | China | CN106794171 | 2034-04-17 | ⤷ Sign Up |
| APG-115 | China | CN111718354 | 2034-04-17 | ⤷ Sign Up |
| APG-115 | European Patent Office | EP3131544 | 2034-04-17 | ⤷ Sign Up |
| APG-115 | Spain | ES2712973 | 2034-04-17 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
